助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   卵巢癌化疗 的翻译结果: 查询用时:0.437秒
图标索引 在分类学科中查询
所有学科
妇产科学
更多类别查询

图标索引 历史查询
 

卵巢癌化疗
相关语句
  chemotherapy for ovarian cancer
     Tumor necrosis factor α and drug-resistance in chemotherapy for ovarian cancer
     肿瘤坏死因子α与卵巢癌化疗耐药
短句来源
  “卵巢癌化疗”译为未确定词的双语例句
     Some anti-chemoresistance and improving the efficacy of cancer therapy, such as SU5416, EpoB, Apo2L/TRAIL, PSC833, TP53, BCL-2, BAX, MEK1 protein, MAPKs, JNK, p38 and ERK, provide the strong support and bring the new hope to improve the effect of chemotherapy.
     一系列具抗耐药和与卵巢癌化疗药物有协同作用的基因SU5416、EpoB、Apo2L/TRAIL、PSC833、TP53、BCL-2、BAX和MEK1蛋白、MAPKs、JNK、p38和ERK的出现,为改善卵巢癌化疗效果,提高治愈率,带来了新的希望。
短句来源
     2. Protein profilings of taxol-sensitive (SKOV3, A2780) and -resistant (SK-TR30, SK-TR2500, A2780-TR)cells were established by two-dimensional gel electrophoresis and identification of candidate protein related taxol-resistance by
     2.采用2-DE,制备卵巢癌化疗敏感细胞株SKOV3、A2780和卵巢癌紫杉醇耐药细胞株SK-TR30、SK-TR2500、A2780-TR蛋白质表达图谱,通过比较蛋
短句来源
     The Role of TopoⅡα、GST-π、P-gp Played in the Multidrug Resistance of the Epithelial Ovarian
     TopoⅡα、GST-π、P-gp在卵巢癌化疗耐药中的作用
短句来源
     The positive expression rate of ERCC1 in chemoresistant group was 77.27%,that of chemosensitive one was 35.00%,with significant difference between the two groups(P<0.05).
     卵巢癌化疗耐药组ERCC1的阳性表达率为77.27%,明显高于敏感组35.00%,组间差异有统计学意义(P<0.05)。
短句来源
     Objective:To study the relation CX43(connexin43) and P-gp(P-Glycoprotein) with chemotherapy curative effect(resistance or sensitivity) and histopathology in PEOC(Primary epithelia ovarian carcinoma).
     目的:探讨细胞间隙连接蛋白43(connexin43,CX43)和P糖蛋白(P鄄Glycoprotein,P鄄gp)与上皮性卵巢癌化疗疗效(耐药或敏感)及临床病理的关系。
短句来源
更多       
  相似匹配句对
     Intraperitoneal chemotherapy for ovarian cancer
     卵巢癌腹腔化疗
短句来源
     The chemotherapy for advanced ovarian carcioma
     晚期卵巢癌化疗
短句来源
     Immunotherapy for ovarian cancer
     卵巢癌的免疫治疗
短句来源
     Chemotherapy was effective.
     化疗有效。
短句来源
查询“卵巢癌化疗”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  chemotherapy for ovarian cancer
Combination chemotherapy for ovarian cancer-lessons not yet learned
      
Consolidation/maintenance chemotherapy for ovarian cancer
      
High-dose chemotherapy for ovarian cancer: Are we ready to go
      
Biomedical engineers, pharmacologists, and clinicians at the NCI have cooperated in the development of a rational chemotherapy for ovarian cancer.
      
Phase II study of carboplatinum/cyclophosphamide combination chemotherapy for ovarian cancer
      
更多          


19 patients with advanced ovariocarcinoma were treated during Novermber 1988 to February 1993.In these cases,9 had recurrent ovariocarcinoma and 10 had metastatic ovariocarcinma.They were given the regimen of combination chemotherapy of cisplatin (DDP) and Adriamycin (ADM).Among the 15 patients with ascites,the remarkable efffects in controlling malignant ascites were gained in 4 cases and ascites reduction was noted in 9 cases.The overall responsece rate was 86.7%.In 9 cases with recurrence the overall response...

19 patients with advanced ovariocarcinoma were treated during Novermber 1988 to February 1993.In these cases,9 had recurrent ovariocarcinoma and 10 had metastatic ovariocarcinma.They were given the regimen of combination chemotherapy of cisplatin (DDP) and Adriamycin (ADM).Among the 15 patients with ascites,the remarkable efffects in controlling malignant ascites were gained in 4 cases and ascites reduction was noted in 9 cases.The overall responsece rate was 86.7%.In 9 cases with recurrence the overall response rate was 77.8%,with 6 patients having complete remmision and 1 patient achiving partial remmision.In second group 3 patients received second operation. In all of these patients,no remarkable toxicity reaction was observed and the survival time was prolonged.One patient has survived for 4 years.The results indicate that the combination chemotherapy of DDP and ADM is a effective regimen for advanced recurrent and inetastatic ovariocarcinoma.

1988年11月至1993年2月共收治卵巢恶性肿瘤19例,其中复发性卵巢癌9例,卵巢转移癌10例。采用以阿霉素、顺铂为主的联合化疗方案,15例有腹水者经上述治疗后,显效4例,有效9例,客观有效率为86.7%;9例复发性卵巢癌化疗后完全缓解6例、部分缓解1例,有效率为77.8%。其中3例再次手术后辅以化疗,生存时间延长,1例已存活4年余。全组未发生严重地毒副作用。治疗结果显示,以阿霉素、顺铂为主的联合化疗方案对复发性和卵巢转移癌不失为一有效的治疗方法。

Most of the advanced ovarian cancer patients are accompanied by ascites which rarely responded tosystemic chemotherpy. Trial with DDP-combined chemotherapy regimen intraperitoneally in patients with advanced ovarian cancer with or without ascites was carried out since 1988 achieving response rate of 90%. The mainstay agent in this regimen was DDP. The drug concentration in ascitic fluid was 25 times that of the serum. No severe toxicity was noted. There was no drug cross-resistance.

晚期卵巢癌多合并腹水,临床上单靠全身用药效果不甚满意.我们于1988年初开始应用以顺铂为主的联合化疗行腹腔注射治疗晚期卵巢癌合并腹水,取得了较好效果,有效率达90%.DDP是卵巢癌化疗的关键药物,腹腔内注入比静脉更具优点,浓度比静脉高25倍,对组织渗透性好,不引起腹腔局部中毒,副作用也较轻;且与其它药物无交叉耐药性,值得临床推广.

The enhanced effect of 4 agents(tamoxifen clomiphene,cyclosporin A and verapamil)wasobserved in vitro on the cytotoxicity of DDP and Taxol on the ovarian cancer cell line by ATP assay. Theresults showed that 4 agents had no cytotoxicity themselves when added alone to the cell line at lower con-centration(1 μg/ml),but they showed enhanced effcets when added with DDP or Taxol.However,athigher concentration(5 μg/ml),tamoxifen,clomiphene and cyclosporin A showed inhibitory effects whenused alone,all 4 agents showed...

The enhanced effect of 4 agents(tamoxifen clomiphene,cyclosporin A and verapamil)wasobserved in vitro on the cytotoxicity of DDP and Taxol on the ovarian cancer cell line by ATP assay. Theresults showed that 4 agents had no cytotoxicity themselves when added alone to the cell line at lower con-centration(1 μg/ml),but they showed enhanced effcets when added with DDP or Taxol.However,athigher concentration(5 μg/ml),tamoxifen,clomiphene and cyclosporin A showed inhibitory effects whenused alone,all 4 agents showed an increased inhibitory rate when they were added with DDP or Taxol atthis concentration and the inhibitory rates were higher than that of chemotherapeutic drtigs or these 4 agentsalone. Either tamoxifen or cyclosporin A showed the stronger effect than that of the other two agents,theymay be used in the chemotherapy of the patients with ovarian cancer as an enhtqncer of DDP and Taxol.Wemeasured estrogen receptor(ER)of this cell line by immunohistochemical method and the result was nega-tive,it was suggested that tamoxifen may be also used in ER-negative ovarian cancer clinically.

本试验用卵巢癌细胞株,采用三磷酸腺苷法(ATP法)分别观察四种化疗增敏剂即三苯氧胺、克罗米酚、环孢菌素A及维拉帕米对顺铂(CDDP)或紫杉醇(Taxol)的体外增效作用。结果显示,各增敏剂在较低浓度(1μg/ml)情况下,单用时均无明显抑瘤作用,但与CDDP或Taxol合用时能增强其在一定剂量下对肿瘤细胞的杀伤作用。各增敏剂在较高浓度(5μg/ml)下,三苯氧胺、克罗米酚及环孢菌素A单用有一定抑瘤作用,此时四药与CDDP或Taxol合用时抑制率增高且高于化疗药物或化疗增敏剂单用时的抑制率。增效作用以三苯氧胺和环孢菌素A最强,故提出可将三苯氧胺或环孢菌素A作为CDDP和Taxol的增效剂用于卵巢癌化疗。另外本文检测该细胞株雌激素受体(FR)为阴性,提示三苯氧胺亦可试用于ER(一)的患者。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关卵巢癌化疗的内容
在知识搜索中查有关卵巢癌化疗的内容
在数字搜索中查有关卵巢癌化疗的内容
在概念知识元中查有关卵巢癌化疗的内容
在学术趋势中查有关卵巢癌化疗的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社